Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?

Anticancer Research

Volumn 17, Issue 3 A, 1997, Pages 1531-1534

  Tarle, Marko ^a   Kraljić, Ivo ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

BPH; Free and total PSA serotest; Low and high grade PIN; PAP; Prostate cancer; TPS

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BLOOD LEVEL; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; HUMAN; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RETROSPECTIVE STUDY;

ALKALINE PHOSPHATASE; HUMANS; IMMUNORADIOMETRIC ASSAY; MALE; PEPTIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RADIOIMMUNOASSAY; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 0030922021     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Christensson A, Laurell C-B and Lilja H: Enzymatic activity of the prostate-specific antigen and its reaction with extracellular serine protease inhibitors. Eur J Biochem 194: 755, 1990.
2. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K and Alfthan O: A complex between prostate-specific antigen and alpha-1-anlichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222, 1991.
3. Christensson, A, Björk, T, Nilsson, O, Dahlen, U, Matikainen, M.-T, Cockett ATK, Abrahamsson P-A and Lilja H.: Serum prostate specific antigen complexed to alpha 1antichymotrypsin as an indicator of prostate cancer. J Urol 150: 100, 1993.
4. Partin AW, Kelly CA, Subong ENP, Walsh PC. Chan DW, Wang TJ, Rittenhouse HG, Wolfert RL, Norton KC, McCormac K: Measurement of the ratio of free PSA and total PSA improves prostate cancer determination for men with total PSA levels between 4.0 and 10.0 ng/ml. J Urol 153 (April Supplement): 295A, 1995.
5. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL: Increased specificity of PSA screening through measurement of free PSA in serum. J Urol 153 (April Supplement): 312A, 1995.
6. Bjork T, Bjartell A, Lilja H, Abrahamsson P-A and di Sant'Agnese A: Occurance of alpha-1-antichymotrypsin in the PSA-producing prostatic epithelium may be a prerequisite for complex-binding of PSA to alpha-1-antichymotrypsin in blood. J Urol Part 2,149: 332A, 1993.
7. Leinonen J, Zhang W-M and Stenman U-H: Complex formation between PSA isoenzymes and protease inhibitors. J Urol 155: 1099-1103, 1966.
8. Tarle M, Rakvin Ž and Kraljić I: The F/T PSA ratio in prostate cancer responders and nonresponders to hormonal therapy and cytostatics: A new reliable prognostic index. Int. Conference of Anticancer Res, Corfu, Greece, October 1995, Anticancer Res 75 (5A):1815, 1995.
9. Algaba F, Epstein JI, Fabus G, Helpap B, Nagle RB and Polito M: Working standards in prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Pathol Res Pract 191: 842, 1995.
10. Tarle M, Kovačič K and Kaštelan M: Correlation of cell proliferation marker (TPS), natural killer (NK) cell activity and tumor load serotest (PSA) in untreated and treated prostatic tumors. Anticancer Res 13: 215, 1993.
11. Mostofi FK, Davis CJ and Sesterhenn IA: Pathology of carcinoma of the prostate. Cancer 70: 235, 1992.
12. Stamey TA, Chen Z and Prestigiacomo A: Serum prostate specific antigen binding alpha1-antichymotrypsin: influence of cancer volume, location and therapeutic selection of resistant clones. J Urol 152: 1510, 1994.
13. Partin AW and Oesterling JE: The clinical usefulness of prostate specific antigen: update 1994. J Urol 152: 1358, 1994.
14. Malard V, Toubert ME, Pons D and Seguin P: Free PSA measurement: A new tool for differential diagnosis of prostate cancer. ISOBM Conference, Montreal, Canada, September 1995, Book of Abstracts, p.87.